Stocks

Drug launch in US bodes well for Dr Reddy’s Labs

| Updated on December 30, 2019 Published on December 30, 2019

 

Dr Reddy’s Laboratories on Monday, announced the launch of Sodium Nitroprusside injection, 50 mg/2 ml (25 mg/ml) single-dose vial,in the United States. The Nitropress brand and generics had US sales of about $8 million MAT for the most recent 12 months ended October 2019 according to IQVIA Health. Dr Reddy’s Sodium Nitroprusside injection is available in single-dose 50 mg/2 ml (25 mg/ml) vials. Nitropress is a trademark of Hospira, Inc. Shares of Dr Reddy’s may react positively to the development.

Published on December 30, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.